Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel C Webb

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology|May 16, 2006
Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasmsMichael A Bidus, Joel C Webb, Jeffrey D Seidman, et al.
Gynecologic Oncology|April 26, 2002
Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?Harriet O Smith, Clifford R Qualls, Audrey A Romero, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2009
Diffuse laminar endocervical glandular hyperplasia: a case reportLouis A Dainty, Thomas C Krivak, Joel C Webb, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology|May 16, 2006
Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasmsMichael A Bidus, Joel C Webb, Jeffrey D Seidman, et al.
Gynecologic Oncology|April 26, 2002
Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?Harriet O Smith, Clifford R Qualls, Audrey A Romero, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2009
Diffuse laminar endocervical glandular hyperplasia: a case reportLouis A Dainty, Thomas C Krivak, Joel C Webb, et al.
Pageof 1